BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
April 23, 2024 08:00 ET
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...
BiomX Announces the Appointment of Susan Blum to its Board of Directors
April 18, 2024 08:00 ET
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
April 04, 2024 07:49 ET
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage...
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 03, 2024 06:30 ET
|
BiomX
Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline Closed concurrent $50 million financing to support BX004 and BX211...
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
March 27, 2024 06:30 ET
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
March 18, 2024 06:30 ET
|
BiomX
Acquisition creates leading phage therapy company with an advanced pipeline that includes two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients...
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
March 06, 2024 07:30 ET
|
BiomX
Acquisition will create phage therapy company with an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients and BX211...
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
January 04, 2024 08:00 ET
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage...
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
November 30, 2023 16:15 ET
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
November 29, 2023 06:30 ET
|
BiomX
BX004 showed clinically meaningful improvement in pulmonary function as measured in FEV11 and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain in a predefined subgroup of patients with...